New drug combo aims to free MDS patients from frequent blood transfusions

NCT ID NCT07096297

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests whether combining luspatercept and darbepoetin alfa can help people with a certain type of lower-risk myelodysplastic syndrome (MDS) need fewer red blood cell transfusions. The study enrolls 60 adults who currently rely on transfusions. Participants receive both drugs every three weeks, and researchers will measure how many achieve transfusion independence for at least 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept and darbepoetin alfa
What this could lead to: If successful, this combination could help many MDS patients need fewer blood transfusions and maintain healthier hemoglobin levels.
What could go wrong: This is an early Phase II trial with only 60 participants, so results may not apply to all MDS patients. The drugs may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS (MYELODYSPLASTIC SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Locations

Harold C. Simmons Comprehensive Cancer Center of UT Southwestern
NOT_YET_RECRUITING

Dallas, Texas, 75235, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
NOT_YET_RECRUITING

Chicago, Illinois, 60611, United States
Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.